Vertex Pharmaceuticals Incorporated secured FDA approval for TRIKAFTA, reinforcing the company’s market dominance in the cystic fibrosis sector and driving revenue forecasts as the product maintains its status as a global blockbuster. This regulatory milestone strengthens investor confidence by mitigating competitive gaps and securing Vertex's position at the forefront of rare disease therapeutics.